TORONTO — Conavi Medical Corp., a commercial-stage medical device company specializing in advanced imaging technologies for minimally invasive cardiovascular procedures, has announced the grant of 1,600,000 incentive stock options to officers of the company. The equity grants were issued pursuant to the terms of the corporation’s Omnibus Equity Incentive Plan and are subject to regulatory clearance from the TSX Venture Exchange.
The Toronto-based medical technology firm, which trades on the TSX Venture Exchange under the ticker symbol CNVI and on the OTCQB Venture Market under CNVIF, established an exercise price of C$0.20 per common share for the newly issued options. Under the provisions of the grant, the options carry a ten-year term from the date of issuance and follow a structured four-year vesting schedule. Specifically, 25 percent of the options will vest on the first anniversary of the grant date, with the remaining 75 percent vesting in equal monthly instalments over the subsequent 36 months, aligning executive retention and performance incentives with the company’s long-term corporate trajectory.
Executive Compensation and Long-Term Corporate Alignment
Equity incentive packages of this nature are a standard mechanism utilized by publicly traded life sciences and medical technology enterprises to attract, incentivize, and retain executive leadership. By structuring equity compensation under an Omnibus Equity Incentive Plan, companies can establish direct alignment between the interests of their key management personnel and those of public shareholders.
The structure of Conavi’s latest option package emphasizes long-term operational commitment through its four-year vesting framework. The initial one-year cliff ensures that no equity benefits accrue immediately, requiring a baseline period of service before any options can be exercised. The subsequent monthly vesting distribution across three years provides ongoing retention incentives across a multi-year horizon, matching the extended timelines typically required to commercialize complex medical hardware, navigate regulatory pathways, and expand clinical adoption within institutional healthcare settings.
Furthermore, with an exercise price set at C$0.20 per share over a ten-year duration, the options tie officer compensation directly to the appreciation of Conavi’s equity valuation in public markets. As with all equity-based transactions conducted by issuers listed on the TSX Venture Exchange, the formal execution and validity of the grant remain subject to regulatory filings and final acceptance under the exchange’s corporate finance and governance policies.
Hybrid Imaging Technology: Addressing Cardiovascular Procedural Needs
Conavi Medical operates within the specialized sector of interventional cardiology, designing, manufacturing, and marketing imaging systems intended to guide minimally invasive procedures. In routine clinical practice, interventional cardiologists perform catheter-based interventions, such as angioplasty and stent placement, to treat coronary artery disease, restore adequate blood flow to ischemic myocardium, and reduce the risk of acute cardiovascular events.
To optimize the placement and expansion of coronary stents and to assess arterial blockages accurately, clinicians increasingly rely on intravascular imaging modalities rather than standard two-dimensional X-ray angiography alone. Traditional angiography provides a luminogram—a silhouette of the vessel interior—which can obscure the true extent of atherosclerotic plaque, vessel wall pathology, and intricate anatomical variations. Intravascular imaging addresses these limitations by offering direct, cross-sectional evaluation from inside the blood vessel.
Conavi’s core technological advancement centers on its patented hybrid imaging system, which integrates two historically distinct diagnostic modalities into a single catheter platform: intravascular ultrasound (IVUS) and optical coherence tomography (OCT).
Historically, interventional cardiologists have had to weigh the distinct physical advantages and trade-offs of IVUS and OCT. Intravascular ultrasound utilizes high-frequency acoustic waves to visualize arterial structures. Because ultrasound waves penetrate deeply through biological tissue, IVUS provides clinicians with a clear view of the entire vessel wall, the external elastic membrane, and the total plaque burden, making it particularly effective for determining true reference vessel size and detecting deep tissue structures. However, acoustic imaging has inherent limits in spatial resolution, which can make fine surface assessments challenging.
Conversely, optical coherence tomography uses near-infrared light to generate microscopic cross-sectional images with substantially higher spatial resolution than ultrasound. This optical approach excels at revealing superficial luminal structures, defining thin-cap fibroatheromas, assessing microscopic thrombus formations, and inspecting whether stent struts are fully apposed against the vessel wall. Nonetheless, because light rapidly scatters in biological tissue and cannot penetrate dense structures or blood, OCT typically offers limited depth of penetration and requires a transient flush of contrast or clear media to clear the blood pool during image acquisition.
Conavi’s proprietary platform represents the first system engineered to co-register and co-align IVUS and OCT imaging beams simultaneously. By synchronizing acoustic sound waves and optical light beams within a single hybrid pullback, the technology is designed to enable interventionalists to evaluate both depth of vessel architecture and high-resolution luminal surface detail at the exact same anatomical location. This co-aligned approach eliminates the historical requirement for operators to choose between imaging modalities or perform separate catheter exchanges, which traditionally added procedural time, heightened patient risk, and increased resource consumption.
Commercial Stage and Regulatory Milestones
Conavi has transitioned from early research and development into a commercial-stage enterprise, having secured 510(k) clearance from the United States Food and Drug Administration (FDA) for its hybrid imaging system. FDA 510(k) clearance is a foundational regulatory benchmark, affirming that the medical device is substantially equivalent in safety and effectiveness to legally marketed predicate devices, thereby authorizing commercial distribution and clinical use across the United States healthcare system.
Securing regulatory clearance enables the company to direct its efforts toward market introduction and targeted commercial launch. Within the medical device landscape, bringing a capital equipment console and disposable imaging catheters to market involves extensive multi-disciplinary execution, including clinical education, health system procurement navigation, hospital value analysis committee reviews, and the establishment of robust manufacturing supply chains capable of meeting rigorous quality standards.
The broader market for coronary intravascular imaging has experienced notable momentum in recent years, driven by a growing body of clinical trial evidence and evolving medical society guidelines. Interventional cardiology guidelines internationally have increasingly elevated the recommended use of intravascular imaging during complex percutaneous coronary intervention (PCI). Clinical studies have consistently shown that imaging-guided stent implantation yields superior procedural outcomes, lower rates of stent thrombosis, reduced target lesion revascularization, and improved long-term patient survival compared to angiographic guidance alone. Conavi aims to position its hybrid system within this expanding clinical paradigm by offering an integrated solution that satisfies the diagnostic capabilities traditionally split across separate devices.
Forward-Looking Considerations and Corporate Information
As Conavi Medical pursues its commercialization strategy, the company’s forward-looking operations involve various strategic objectives and operational assumptions. Management has identified several focal points critical to its commercial trajectory, including the scheduled commercial rollout of the hybrid imaging system, the adequacy of available working capital and financial resources to fund commercialization milestones, the rate of global market adoption for IVUS and OCT technologies, and the continued integration of intravascular imaging into standard cardiovascular guidelines.
As detailed in the company’s continuous disclosure filings, actual results may differ from management’s projections due to standard risks inherent in commercial-stage medical technology enterprises. These factors include the rate of institutional adoption among hospitals and cardiac catheterization laboratories, manufacturing scale-up challenges, the competitive landscape of the intravascular imaging market, ongoing regulatory and quality compliance, and broader capital market conditions. Comprehensive details regarding the company’s operating profile and associated risk factors remain available through public filings on the SEDAR+ electronic system under Conavi’s profile, including its Annual Information Form.
Corporate and investor relations inquiries regarding Conavi Medical Corp. and its Omnibus Equity Incentive Plan are handled by Chief Financial Officer Mark Quick and Investor Relations representative Christina Cameron at the company’s Toronto headquarters.